Publikation

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

Wissenschaftlicher Artikel/Review - 01.03.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive P, Mueller C, Müller S, Naegelin Y, Oksenberg J, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani M, Granziera C, Piehl F, Leppert D, Kuhle J, ĀăąĆĉČĎ Ā. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 2022; 21:246-257.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Lancet Neurol 2022; 21
Veröffentlichungsdatum
01.03.2022
eISSN (Online)
1474-4465
Seiten
246-257
Kurzbeschreibung/Zielsetzung

Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease-modifying therapies.